References
Ansbacher R. Generic drugs: bioequivalence and bioavailability. Journal of the American Medical Association 259: 220, 1988
Ansbacher R, Schneider CR. Lack of therapeutic effectiveness of generic conjugated estrogens. American Journal of Gynecologic Health 4: 146–148, 1990
Drug Price Competition and Patent Term Restoration Act. Congressional Record, 5-10981, Washington, September 12, 1984
Editorial. Conjugated estrogen tablets, USP. United States Pharmacopeia XXI, United States Pharmacopeial Convention, Inc., Rockville, Maryland, 1985
Editorial. Conjugated estrogens bioequivalence should not be based on urinary excretion studies, FDA committee says; panel suggests long-term efficacy studies. F-D-C Reports ‘Pink Sheet’ 51(2): 12, January 9, 1989a
Editorial. Conjugates estrogen bioequivalance tests: FDA would accept single-dose study if AUC and Cmax values fall in 80–120% range; June 16 draft. F-D-C Reports ‘Pink Sheet’ 51(26): June 26, 1989b
Nichols KC, Schenkel L, Benson H. 17-beta estradiol for postmenopausal estrogen replacement therapy. Obstetrical and Gynecological Survey 39: 230–245, 1984
United States Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management. Approved drug products with therapeutic equivalence evaluations, 9th ed., 1989
Wall Street Journal, p. 8, December 13, 1989
Washington Drug Letter, p. 6, May 13, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ansbacher, R. Bioequivalence of Conjugated Estrogen Products. Clin. Pharmacokinet. 24, 271–274 (1993). https://doi.org/10.2165/00003088-199324040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199324040-00001